138 related articles for article (PubMed ID: 9587050)
41. Pharmacokinetics of small doses of methotrexate in patients with psoriasis.
Kamel RS; al-Hakiem MH; Rademaker M; Meyrick Thomas RH; Munro DD
Acta Derm Venereol; 1988; 68(3):267-70. PubMed ID: 2455425
[TBL] [Abstract][Full Text] [Related]
42. Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies.
Mougenot P; Pinguet F; Fabbro M; Culine S; Poujol S; Astre C; Bressolle F
Cancer Chemother Pharmacol; 2004 Jun; 53(6):503-12. PubMed ID: 15007638
[TBL] [Abstract][Full Text] [Related]
43. Population pharmacokinetics of amikacin in geriatric patients studied with the NPEM-2 algorithm.
Debord J; Charmes JP; Marquet P; Merle L; Lachâtre G
Int J Clin Pharmacol Ther; 1997 Jan; 35(1):24-7. PubMed ID: 9021438
[TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetics of low-dose methotrexate in adult asthmatics.
Glynn-Barnhart AM; Erzurum SC; Leff JA; Martin RJ; Cochran JE; Cott GR; Szefler SJ
Pharmacotherapy; 1992; 12(5):383-90. PubMed ID: 1437699
[TBL] [Abstract][Full Text] [Related]
45. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
van den Bongard HJ; Mathôt RA; van Tellingen O; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2002 Jul; 50(1):16-24. PubMed ID: 12111107
[TBL] [Abstract][Full Text] [Related]
46. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients.
Irtan S; Saint-Marcoux F; Rousseau A; Zhang D; Leroy V; Marquet P; Jacqz-Aigrain E
Ther Drug Monit; 2007 Feb; 29(1):96-102. PubMed ID: 17304156
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of Bayesian estimation to discriminate subpopulations of patients with altered pharmacokinetics using fragmentary data: a pilot study with pefloxacin.
Bruno R; Rosier P; Iliadis A; Le Roux Y; Montay G; Frydman A; Gaillot J
Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():338-45. PubMed ID: 1820906
[TBL] [Abstract][Full Text] [Related]
48. High dose methotrexate in adult patients with osteosarcoma: clinical and pharmacokinetic results.
Comandone A; Passera R; Boglione A; Tagini V; Ferrari S; Cattel L
Acta Oncol; 2005; 44(4):406-11. PubMed ID: 16120550
[TBL] [Abstract][Full Text] [Related]
49. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
Guo F; Letrent SP; Sharma A
Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
[TBL] [Abstract][Full Text] [Related]
50. Folic acid alters methotrexate availability in patients with rheumatoid arthritis.
Bressolle F; Kinowski JM; Morel J; Pouly B; Sany J; Combe B
J Rheumatol; 2000 Sep; 27(9):2110-4. PubMed ID: 10990220
[TBL] [Abstract][Full Text] [Related]
51. Open-loop feedback control of serum bentazepam concentrations and Bayesian estimation in multiple dosage regimens in patients.
Colino CI; Lastra CF; López FG; Ledesma A; Mariño EL
Int J Clin Pharmacol Ther Toxicol; 1991 Nov; 29(11):457-62. PubMed ID: 1800395
[TBL] [Abstract][Full Text] [Related]
52. Modeling plasma and saliva topotecan concentration time course using a population approach.
Boucaud M; Pinguet F; Culine S; Poujol S; Astre C; Gomeni R; Bressolle F
Oncol Res; 2003; 13(4):211-9. PubMed ID: 12659422
[TBL] [Abstract][Full Text] [Related]
53. A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis.
Westhovens R; Houssiau F; Joly J; Everitt DE; Zhu Y; Sisco D; Van Hartingsveldt B; Mascelli MA; Graham MA; Durez P; Bouman-Thio E
J Rheumatol; 2006 May; 33(5):847-53. PubMed ID: 16583466
[TBL] [Abstract][Full Text] [Related]
54. The pharmacokinetics and pharmacodynamics of fludarabine in rheumatoid arthritis.
Knebel W; Davis JC; Sanders WD; Fessler B; Yarboro C; Pucino F; Boumpas DT
Pharmacotherapy; 1998; 18(6):1224-9. PubMed ID: 9855320
[TBL] [Abstract][Full Text] [Related]
55. Simulation of plasma bentazepam levels in multiple dosage regimens from parameters established by non-linear regression and bayesian estimation.
Mariño EL; Fernandez Lastra C; Gonzalez Lopez F; Martin Rey A; Dominguez-Gil A; Garcia-Santalla JL; Llorca G; Izquiexdo JA; Ledesma-Jimeno A
Int J Clin Pharmacol Ther Toxicol; 1987 Dec; 25(12):664-9. PubMed ID: 2893777
[TBL] [Abstract][Full Text] [Related]
56. Population pharmacokinetics of oral busulfan in children.
Schiltmeyer B; Klingebiel T; Schwab M; Mürdter TE; Ritter CA; Jenke A; Ehninger G; Gruhn B; Würthwein G; Boos J; Hempel G
Cancer Chemother Pharmacol; 2003 Sep; 52(3):209-16. PubMed ID: 12811512
[TBL] [Abstract][Full Text] [Related]
57. Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis.
Karim A; Tolbert DS; Hunt TL; Hubbard RC; Harper KM; Geis GS
J Rheumatol; 1999 Dec; 26(12):2539-43. PubMed ID: 10606360
[TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetics of high and moderate intravenous doses of methotrexate.
Awidi A; al-Turk A; Madanat F; Othman S; Shaheen O
Res Commun Chem Pathol Pharmacol; 1988 Mar; 59(3):411-4. PubMed ID: 3363225
[TBL] [Abstract][Full Text] [Related]
59. The effects of food on methotrexate absorption.
Hamilton RA; Kremer JM
J Rheumatol; 1995 Apr; 22(4):630-2. PubMed ID: 7791153
[TBL] [Abstract][Full Text] [Related]
60. Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma.
Rousseau A; Sabot C; Delepine N; Delepine G; Debord J; Lachâtre G; Marquet P
Clin Pharmacokinet; 2002; 41(13):1095-104. PubMed ID: 12403645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
